Loading…
Active-site mutations of diphtheria toxin. Tryptophan 50 is a major determinant of NAD affinity
The two active-site tryptophans of diphtheria toxin, Trp-50 and Trp-153, were individually or jointly replaced with phenylalanine or alanine by directed mutagenesis of a synthetic gene for the toxin's catalytic A fragment. Substitution of Trp-50 with alanine (W50A) decreased the ADP-ribosyltran...
Saved in:
Published in: | The Journal of biological chemistry 1994-09, Vol.269 (37), p.23296-23301 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The two active-site tryptophans of diphtheria toxin, Trp-50 and Trp-153, were individually or jointly replaced with phenylalanine
or alanine by directed mutagenesis of a synthetic gene for the toxin's catalytic A fragment. Substitution of Trp-50 with alanine
(W50A) decreased the ADP-ribosyltransferase activity by nearly 10(5)-fold and reduced NAD-glycohydrolase activity beyond the
limits of our detection. Effects of the W153A mutation on these activities were less dramatic, < 40-fold decrease in ADP-ribosylation
and < 10-fold decrease in NAD glycohydrolysis. The W50F and W153F substitutions caused only minimal reductions (< 2-fold)
in enzyme activities and NAD affinity. Decreases in affinity for NAD in the initial, ground state complex, as measured by
intrinsic protein fluorescence, correlated well with the reductions in enzyme activity. None of the mutations caused greater
than a 10-fold decrease in NAD affinity for the ternary Michaelis complex in the ADP-ribosylation reaction; and none caused
significant increase in susceptibility to proteolytic digestion by trypsin. The results indicate that Trp-50 is a major determinant
of NAD affinity. Also, they identify this residue as a candidate for modification in the development of inactive forms of
the toxin for use in vaccine development. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1016/S0021-9258(17)31653-8 |